Oral 16:RI Therapy・PSMA・Others

[1-MO16-5] PK/Dosimetry of 177Lu-PSMA-617 and 68Ga-PSMA-11 in Japanese Patients with PSMA+ mCRPC

Anri Inaki¹、Shoko Takano²、Kenji Hirata³、Masahiko Sato⁴、Satoshi Nomura⁴、Toru Hattori⁴、Hiroya Kambara⁴、Tohru Shiga⁵、Makoto Hosono⁶ (1.Division of Functional Imaging, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan、2.Department of Radiation Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan、3.Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan、4.Novartis Pharma K.K., Tokyo, Japan、5.Department of Nuclear Medicine, Fukushima Medical University, Fukushima, Japan、6.Department of Radiology, Kindai University, Osaka, Japan)